Male Pattern Hair Loss (Hamilton-Norwood IIv–V) When Finasteride and Minoxidil Have Not Worked

This protocol addresses male patients aged 18 and older with mild to moderate androgenetic alopecia (Hamilton-Norwood IIv–V) who have already received first-line therapy and have not achieved adequate control of hair loss or meaningful hair regrowth.

Previous treatment — goals not reached

First-line therapy combining oral Finasteride and topical Minoxidil did not adequately stop hair shedding or induce measurable hair regrowth. Failure to achieve these two targets — cessation of hair loss and increase in hair count — is the clinical trigger for escalation to this next-step protocol.

Next-step approach

A second-line 5-alpha reductase inhibitor — distinct from the agent used in the first-line regimen — is evaluated as the next therapeutic step in this setting…

Full regimen, dosing, monitoring guidance, and complete algorithm are in the structured protocol below.

Goal: stop hair loss Goal: increase hair count

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jdv.14624

Topical Minoxidil 2–5% solution 1 mL or half a cap of 5% foam twice daily is recommended to improve or to prevent progression of AGA in male patients above 18 years with mild to moderate AGA (Hamilton-Norwood IIv-V).

Oral Finasteride 1 mg/day is recommended to improve or to prevent progression of AGA in male patients above 18 years with mild to moderate AGA (Hamilton-Norwood IIv-V).

Oral Dutasteride 0.5 mg/day can be considered in case of ineffective previous treatment with 1 mg finasteride over 12 months as a second line treatment to improve or to prevent progression of AGA in male patients above 18 years with mild to moderate AGA (Hamilton-Norwood IIIv-V).

View source ↗